WHAT WE DO
Actively Transported Lysophospholipids (ATLs) are a promising new class of lipid-based therapeutics that are actively transported by the major facilitator superfamily domain–containing 2a (MFSD2a) protein in a tissue specific manner. Vanteres focuses on using its knowledge of MFSD2a biology to develop ATLs for a wide range of disease states.
